November 29, 2016 - By Adrian Mccoy
In an analyst report made public on Tuesday morning, Oxford BioMedica PLC (LON:OXB) stock Hold was reaffirmed by N+1 Singer. They currently have a GBX 3.30 PT on the stock. N+1 Singer’s PT would suggest a potential downside of -6.52% from the company’s last stock price.
Out of 2 analysts covering Oxford BioMedica PLC (LON:OXB), 1 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 50% are positive. GBX 330 is the highest target while GBX 6 is the lowest. The GBX 169 average target is 4660.56% above today’s (GBX 3.55) stock price. Oxford BioMedica PLC has been the topic of 7 analyst reports since August 27, 2015 according to StockzIntelligence Inc. N+1 Singer maintained Oxford BioMedica plc (LON:OXB) rating on Monday, November 16. N+1 Singer has “Buy” rating and GBX 11 price target. The stock has “Hold” rating given by N+1 Singer on Friday, October 14. The firm has “Sell” rating by N+1 Singer given on Monday, March 7. The firm earned “Buy” rating on Friday, January 29 by N+1 Singer. The stock of Oxford BioMedica plc (LON:OXB) has “Buy” rating given on Thursday, August 27 by N+1 Singer. N+1 Singer maintained the shares of OXB in a report on Wednesday, November 4 with “Buy” rating.
About 10.41M shares traded hands or 179.09% up from the average. Oxford BioMedica plc (LON:OXB) has declined 38.07% since April 29, 2016 and is downtrending. It has underperformed by 43.33% the S&P500.
Oxford BioMedica plc is a gene and cell therapy company. The company has a market cap of 109.00 million GBP. The Firm is engaged in lentiviral vector and cell therapy research, development and production. It currently has negative earnings. The Company’s divisions include Partnering, and R&D.
More recent Oxford BioMedica plc (LON:OXB) news were published by: Uk.Finance.Yahoo.com which released: “Oxford BioMedica PLC (OXB.L)” on March 29, 2014. Also Fool.Co.Uk published the news titled: “Should you buy Blinkx plc, Oxford BioMedica plc and Intelligent Energy Holding …” on May 17, 2016. Fool.Co.Uk‘s news article titled: “Should You Buy Oxford BioMedica plc After Novartis AG Deal Sends Shares Surging?” with publication date: October 10, 2014 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Adrian Mccoy